Difference between revisions of "Typical carcinoid lung tumour"

From Libre Pathology
Jump to navigation Jump to search
Line 76: Line 76:
**[[Atypical lung carcinoid tumour|Atypical carcinoid]] is on average 17% (range 10-26%).<ref name=pmid25318848/>
**[[Atypical lung carcinoid tumour|Atypical carcinoid]] is on average 17% (range 10-26%).<ref name=pmid25318848/>


[[Neuroendocrine markers]]:<ref name=pmid25006841>{{Cite journal  | last1 = Sayeg | first1 = Y. | last2 = Sayeg | first2 = M. | last3 = Baum | first3 = RP. | last4 = Kulkarni | first4 = HR. | last5 = Presselt | first5 = N. | last6 = Mäder | first6 = I. | last7 = Kunze | first7 = A. | last8 = Sänger | first8 = J. | last9 = Hörsch | first9 = D. | title = [Pulmonary neuroendocrine neoplasms]. | journal = Pneumologie | volume = 68 | issue = 7 | pages = 456-77 | month = Jul | year = 2014 | doi = 10.1055/s-0034-1365642 | PMID = 25006841 }}</ref>
[[Neuroendocrine markers]]:<ref name=pmid25006841>{{Cite journal  | last1 = Sayeg | first1 = Y. | last2 = Sayeg | first2 = M. | last3 = Baum | first3 = RP. | last4 = Kulkarni | first4 = HR. | last5 = Presselt | first5 = N. | last6 = Mäder | first6 = I. | last7 = Kunze | first7 = A. | last8 = Sänger | first8 = J. | last9 = Hörsch | first9 = D. | title = [Pulmonary neuroendocrine neoplasms]. | journal = Pneumologie | volume = 68 | issue = 7 | pages = 456-77 | month = Jul | year = 2014 | doi = 10.1055/s-0034-1365642 | PMID = 25006841 }}</ref><ref name=pmid23676981>{{Cite journal  | last1 = Zhu | first1 = L. | last2 = Shen-Tu | first2 = Y. | last3 = Zhang | first3 = J. | last4 = Fan | first4 = X. | title = [Pathological characteristic and clinical management of pulmonary carcinoid]. | journal = Zhongguo Fei Ai Za Zhi | volume = 16 | issue = 5 | pages = 246-51 | month = May | year = 2013 | doi = 10.3779/j.issn.1009-3419.2013.05.06 | PMID = 23676981 }}</ref>
*Chromogranin A +ve.
*Chromogranin A +ve.
*Synaptophysin +ve.
*Synaptophysin +ve.

Revision as of 01:58, 30 October 2015

Typical carcinoid lung tumour
Diagnosis in short

Lung carcinoid. H&E stain.

Synonyms lung carcinoid

LM stippled chromatin, usually nested architecture, no necrosis, low mitotic rate (see below)
LM DDx atypical carcinoid lung tumour, pulmonary carcinoid tumourlet, lung adenocarcinoma
IHC Ki-67 ~2% (0-7%), TTF-1 +ve/-ve, CK7 +ve/-ve, CK20 -ve
Gross well-circumscribed, solid, >=5 mm (definition)
Site lung - see lung tumours

Syndromes diffuse idiopathic pulmonary neuroendocrine cell hyperplasia

Symptoms +/-cough, +/-hemoptysis
Prevalence not common
Radiology usually central (85% of cases), well-circumscribed, solid
Prognosis benign
Clin. DDx other lung tumours, lung metastases (esp. when multiple)
Treatment excision to exclude other types of lung tumours & treat symptoms

Typical carcinoid lung tumour, also lung carcinoid and carcinoid tumour of the lung, is a benign lung tumour, that is excised to exclude malignancy.

General

Presentation:[6]

  • Cough.
  • Hemoptysis.

Treatment:

  • Surgical resection.[7]

Gross

  • Well-circumscribed, solid.
  • Location - central airways (85%), remainder peripheral.[8]

Microscopic

Features:

  • Nests of cells.
    • Stippled chromatin.
    • Moderate cytoplasm.
  • No necrosis.
  • Low mitotic rate.
  • Size criterion: >= 5 mm.[9][10]

DDx:

Images

IHC

Proliferation:

Neuroendocrine markers:[13][14]

  • Chromogranin A +ve.
  • Synaptophysin +ve.
  • CD56 +ve.

Others:

  • TTF-1 +ve/-ve (11 +ve of 16 cases[15]).
  • CK7 +ve/-ve (10 +ve of 16 cases[15]).
  • CK20 -ve (0 +ve of 16 cases[15]).

Sign out

A. Lymph Node, Station 2L, Lymphadenectomy:
- Lymph node, NEGATIVE for malignancy.

B. Lymph Node, Station 4L, Lymphadenectomy:
- Lymph node, NEGATIVE for malignancy.

C. Lymph Node, Station 11L, Lymphadenectomy:
- Lymph node, NEGATIVE for malignancy.

D. Lung, Left Upper Lobe, Lobectomy:
- Typical carcinoid tumour (12 mm maximal dimension).
- Carcinoid tumourlet (2 mm maximal dimension).
- Margins clear of tumour.
- Please see tumour summary.

See also

References

  1. Naalsund, A.; Rostad, H.; Strøm, EH.; Lund, MB.; Strand, TE. (Apr 2011). "Carcinoid lung tumors--incidence, treatment and outcomes: a population-based study.". Eur J Cardiothorac Surg 39 (4): 565-9. doi:10.1016/j.ejcts.2010.08.036. PMID 20888248.
  2. Miller, MA.; Mark, GJ.; Kanarek, D. (Aug 1978). "Multiple peripheral pulmonary carcinoids and tumorlets of carcinoid type, with restrictive and obstructive lung disease.". Am J Med 65 (2): 373-8. PMID 356600.
  3. Aubry, MC.; Thomas, CF.; Jett, JR.; Swensen, SJ.; Myers, JL. (Jun 2007). "Significance of multiple carcinoid tumors and tumorlets in surgical lung specimens: analysis of 28 patients.". Chest 131 (6): 1635-43. doi:10.1378/chest.06-2788. PMID 17400673.
  4. Wirtschafter, E.; Walts, AE.; Liu, ST.; Marchevsky, AM. (Jun 2015). "Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia of the Lung (DIPNECH): Current Best Evidence.". Lung. doi:10.1007/s00408-015-9755-1. PMID 26104490.
  5. Chauhan, A.; Ramirez, RA. (Jun 2015). "Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) and the Role of Somatostatin analogs: A Case Series.". Lung. doi:10.1007/s00408-015-9754-2. PMID 26112453.
  6. Gungor, S.; Damadoglu, E.; Aybatli, A.; Yilmaz, A.; Kir, A.; Akkaya, E. (Jul 2006). "Typical pulmonary carcinoid tumors: presentation and outcome of 24 cases.". Med Sci Monit 12 (7): CR315-8. PMID 16810137.
  7. Caplin, ME.; Baudin, E.; Ferolla, P.; Filosso, P.; Garcia-Yuste, M.; Lim, E.; Oberg, K.; Pelosi, G. et al. (Aug 2015). "Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.". Ann Oncol 26 (8): 1604-20. doi:10.1093/annonc/mdv041. PMID 25646366.
  8. Meisinger, QC.; Klein, JS.; Butnor, KJ.; Gentchos, G.; Leavitt, BJ. (Nov 2011). "CT features of peripheral pulmonary carcinoid tumors.". AJR Am J Roentgenol 197 (5): 1073-80. doi:10.2214/AJR.10.5954. PMID 22021498.
  9. URL: http://pathhsw5m54.ucsf.edu/case7/image75.html. Accessed on: 23 January 2012.
  10. He, P.; Gu, X.; Wu, Q.; Lin, Y.; Gu, Y.; He, J. (Dec 2012). "Pulmonary carcinoid tumorlet without underlying lung disease: analysis of its relationship to fibrosis.". J Thorac Dis 4 (6): 655-8. doi:10.3978/j.issn.2072-1439.2012.06.11. PMID 23205296.
  11. Demirci, I.; Herold, S.; Kopp, A.; Flaßhove, M.; Klosterhalfen, B.; Janßen, H. (2012). "Overdiagnosis of a typical carcinoid tumor as an adenocarcinoma of the lung: a case report and review of the literature.". World J Surg Oncol 10: 19. doi:10.1186/1477-7819-10-19. PMID 22269186.
  12. 12.0 12.1 Liu, SZ.; Staats, PN.; Goicochea, L.; Alexiev, BA.; Shah, N.; Dixon, R.; Burke, AP. (2014). "Automated quantification of Ki-67 proliferative index of excised neuroendocrine tumors of the lung.". Diagn Pathol 9: 174. doi:10.1186/s13000-014-0174-z. PMID 25318848.
  13. Sayeg, Y.; Sayeg, M.; Baum, RP.; Kulkarni, HR.; Presselt, N.; Mäder, I.; Kunze, A.; Sänger, J. et al. (Jul 2014). "[Pulmonary neuroendocrine neoplasms].". Pneumologie 68 (7): 456-77. doi:10.1055/s-0034-1365642. PMID 25006841.
  14. Zhu, L.; Shen-Tu, Y.; Zhang, J.; Fan, X. (May 2013). "[Pathological characteristic and clinical management of pulmonary carcinoid].". Zhongguo Fei Ai Za Zhi 16 (5): 246-51. doi:10.3779/j.issn.1009-3419.2013.05.06. PMID 23676981.
  15. 15.0 15.1 15.2 Cai, YC.; Banner, B.; Glickman, J.; Odze, RD. (Oct 2001). "Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors.". Hum Pathol 32 (10): 1087-93. doi:10.1053/hupa.2001.28245. PMID 11679943.